Results 11 to 20 of about 30,645 (194)
TUBB1 promoter methylation is a promising biomarker for predicting HBeAg seroconversion in chronic hepatitis B [PDF]
The identification of predictive indices for hepatitis B e antigen seroconversion (HBeAg SC) in patients with chronic hepatitis B (CHB) remains a challenge.
Tong Zhao +7 more
doaj +4 more sources
Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion [PDF]
It is well appreciated that ethnicity influences the natural history and immune responses during a chronic hepatitis B infection. In this study, we explore the effect of ethnicity and treatment cessation on Hepatitis B surface Antigen (HBsAg ...
Stijn Van Hees +12 more
doaj +4 more sources
Hepatitis B virus (HBV) infection is a worldwide health problem. Consensus guidelines for the treatment of chronic HBV in children have not been established, and indications for antiviral therapy in adults with chronic HBV infection may not be applicable
Mohammed Y Hasosah +4 more
doaj +4 more sources
Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion. [PDF]
UNLABELLED:It has been observed that enlargement of perihepatic lymph nodes may be seen in patients with chronic hepatitis B, particularly during acute flares of CHB.
Yen-Ling Ko +9 more
doaj +5 more sources
BackgroundHBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine ...
Tongjing Xing +3 more
doaj +2 more sources
359 INCREASE RISK OF HBeAg-NEGATIVE CHRONIC HEPATITIS B WITH OLDER AGE AT HBeAg SEROCONVERSION
Background: Recent evidence suggests that delayed HBeAg seroconversion is associated with poorer outcome. We aim to determine the incidence of HBeAg-negative chronic hepatitis B (CHB) according to the age at which HBeAg seroconversion occurs. Methods:
J. Fung +4 more
openaire +2 more sources
Background: We aimed to evaluate the usefulness of serum hepatitis B virus core-related antigens (HBcrAg) for predicting hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients treated with conventional interferon (IFN)
Hui Ma +4 more
doaj +2 more sources
Shaohang Cai,* Zhandong Li,* Tao Yu, Muye Xia, Jie Peng Department of Infectious Diseases and Hepatology Unit, NanFang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China *These authors contributed equally to this ...
Cai S, Li Z, Yu T, Xia M, Peng J
doaj +1 more source
SummaryHBeAg seroconversion marks an important spontaneous change and treatment end‐point for HBeAg‐positive patients and is a pre‐requisite for HBsAg loss or functional cure. In this retrospective analysis, we aimed to identify predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg‐positive patients treated with nucleos(t)ide
B. Wang +5 more
openaire +4 more sources
We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6 +/- 14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4 +/- 4.5 months.
G. D'Ettorre +8 more
openaire +3 more sources

